210 related articles for article (PubMed ID: 17224859)
21. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.
Stuedal A; Ma H; Bjørndal H; Ursin G
Climacteric; 2009 Jun; 12(3):248-58. PubMed ID: 19387884
[TBL] [Abstract][Full Text] [Related]
22. Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women.
García-Pérez MA; Moreno-Mercer J; Tarín JJ; Cano A
Gynecol Endocrinol; 2006 Apr; 22(4):179-84. PubMed ID: 16723303
[TBL] [Abstract][Full Text] [Related]
23. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.
McKeever C; McIlwain H; Greenwald M; Gupta N; Jayawardene S; Huels G; Roberts M
Clin Ther; 2000 Jul; 22(7):845-57. PubMed ID: 10945511
[TBL] [Abstract][Full Text] [Related]
24. Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy.
van Dijck JA; Otten JD; Karssemeijer N; Kenemans P; Verbeek AL; van der Mooren MJ
Climacteric; 2011 Dec; 14(6):683-8. PubMed ID: 21942620
[TBL] [Abstract][Full Text] [Related]
25. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors.
Cauley JA; Song J; Dowsett SA; Mershon JL; Cummings SR
Breast Cancer Res Treat; 2007 Apr; 102(2):181-8. PubMed ID: 17028986
[TBL] [Abstract][Full Text] [Related]
27. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
[TBL] [Abstract][Full Text] [Related]
28. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer risk in postmenopausal women using estrogen-only therapy.
Lyytinen H; Pukkala E; Ylikorkala O
Obstet Gynecol; 2006 Dec; 108(6):1354-60. PubMed ID: 17138766
[TBL] [Abstract][Full Text] [Related]
30. Influence of different HRT regimens on mammographic density.
Junkermann H; von Holst T; Lang E; Rakov V
Maturitas; 2005 Feb; 50(2):105-10. PubMed ID: 15653007
[TBL] [Abstract][Full Text] [Related]
31. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
32. [Effects of hormonal replacement therapy on breast density in postmenopausal women].
Bisanti T; Cavalieri AP; Capri O; Galoppi P; De Felice C; Porfiri LM; Perrone G
Minerva Ginecol; 2004 Apr; 56(2):125-30. PubMed ID: 15258540
[TBL] [Abstract][Full Text] [Related]
33. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density.
Hofling M; Lundström E; Azavedo E; Svane G; Hirschberg AL; von Schoultz B
Climacteric; 2007 Apr; 10(2):155-63. PubMed ID: 17453864
[TBL] [Abstract][Full Text] [Related]
34. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.
Huang AJ; Ettinger B; Vittinghoff E; Ensrud KE; Johnson KC; Cummings SR
J Bone Miner Res; 2007 Nov; 22(11):1791-7. PubMed ID: 17620054
[TBL] [Abstract][Full Text] [Related]
35. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
36. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
37. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
[TBL] [Abstract][Full Text] [Related]
38. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.
Lundström E; Söderqvist G; Svane G; Azavedo E; Olovsson M; Skoog L; von Schoultz E; von Schoultz B
Fertil Steril; 2006 Apr; 85(4):989-95. PubMed ID: 16580385
[TBL] [Abstract][Full Text] [Related]
39. [A mammographic evaluation of the morphostructural variations of the breast during hormone-replacement therapy in the postmenopause].
Porfiri LM; Costanza L; De Felice C; Perrone G; David V; Zichella L
Radiol Med; 1998 Jun; 95(6):573-6. PubMed ID: 9717537
[TBL] [Abstract][Full Text] [Related]
40. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
